SGLT-2 inhibitors were associated with lower risk of renal outcome as compared with placebo (36% lower risk), DPP-4 inhibitors (40% lower risk) and GLP-1RA (22% lower risk)
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Some people report burning, tingling or increased skin sensitivity, Kratovil says
A 2025 systematic review mapped weight change after stopping anti-obesity medicines across 11 RCTs
Therefore, there is no officially approved dosing guidance for general clinical use at this time
Whats most discouraging is that even though Ive been so strict with my diet , my weight hasnt changed at all, and my blood sugar was all over the place